INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29201, 11581, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29202, 11862, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29203, 11863, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29204, 13885, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29205, 23941, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29206, 23943, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29207, 27880, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29208, 28384, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29209, 28386, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29210, 28388, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29211, 28390, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29212, 28391, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29213, 28684, 'Tramadol', 'Liver Diseases', 'Tramadol is converted by the liver to several metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself.  The metabolism of both tramadol and M1 has been shown to decrease in patients with advanced cirrhosis of the liver, resulting in increased exposure to tramadol as well as substantially prolonged elimination half-lives for both tramadol and M1.  Therapy with tramadol should be administered cautiously in patients with liver dysfunction.  In patients with severe liver dysfunction, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29214, 481, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29215, 482, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29216, 484, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29217, 2999, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29218, 3000, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29219, 3002, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29220, 3003, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29221, 3004, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29222, 11150, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29223, 11576, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29224, 11578, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29225, 11579, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29226, 11580, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29227, 11581, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29228, 11862, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29229, 11863, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29230, 13885, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29231, 23941, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29232, 23943, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29233, 27880, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29234, 28384, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29235, 28386, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29236, 28388, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29237, 28390, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29238, 28391, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29239, 28684, 'Tramadol', 'Kidney Diseases', 'Tramadol and its metabolites, one of which (referred to as M1) is pharmacologically active and a more potent analgesic than tramadol itself, are primarily excreted in the urine.  The rate and extent of excretion of both tramadol and M1 have been shown to decrease in patients with impaired renal function.  Therapy with tramadol should be administered cautiously in such patients.  In patients with CrCl less than 30 mL/min, dosage reduction is recommended with the immediate-release formulations, while the extended-release formulations should not be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29240, 481, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29241, 482, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29242, 484, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29243, 2999, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29244, 3000, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29245, 3002, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29246, 3003, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29247, 3004, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29248, 11150, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29249, 11576, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29250, 11578, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29251, 11579, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29252, 11580, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29253, 11581, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29254, 11862, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29255, 11863, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29256, 13885, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29257, 23941, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29258, 23943, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29259, 27880, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29260, 28384, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29261, 28386, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29262, 28388, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29263, 28390, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29264, 28391, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29265, 28684, 'Tramadol', 'Epilepsy', 'Seizures have been reported in patients receiving tramadol within the recommended dosage range.  The risk appears to increase with doses above the recommended range and with concomitant use of certain drugs (e.g., those that reduce the seizure threshold).  Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (e.g., head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).  In tramadol overdose, naloxone administration may increase the risk of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29266, 481, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29267, 482, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29268, 484, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29269, 2999, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29270, 3000, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29271, 3002, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29272, 3003, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29273, 3004, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29274, 11150, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29275, 11576, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29276, 11578, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29277, 11579, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29278, 11580, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29279, 11581, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29280, 11862, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29281, 11863, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29282, 13885, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29283, 23941, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29284, 23943, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29285, 27880, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29286, 28384, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29287, 28386, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29288, 28388, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29289, 28390, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29290, 28391, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29291, 28684, 'Tramadol', 'Depressive Disorder', 'Tramadol should not be prescribed for patients who are suicidal or addiction-prone.  The use of nonnarcotic analgesics should be considered for patients who are suicidal or depressed.  Tramadol should be prescribed with caution for patients with history of misuse and/or are currently taking CNS-active drugs, antidepressant drugs, alcohol in excess, and patients who suffer from emotional disturbance or depression.  Patients should be advised not to exceed the recommended dose and to limit their intake of alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29292, 74, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29293, 81, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29294, 82, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29295, 90, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29296, 91, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29297, 12248, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29298, 13352, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29299, 15595, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29300, 18629, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
